CN100577174C - 含有限定的氧化磷脂的组合物 - Google Patents

含有限定的氧化磷脂的组合物 Download PDF

Info

Publication number
CN100577174C
CN100577174C CN01822215A CN01822215A CN100577174C CN 100577174 C CN100577174 C CN 100577174C CN 01822215 A CN01822215 A CN 01822215A CN 01822215 A CN01822215 A CN 01822215A CN 100577174 C CN100577174 C CN 100577174C
Authority
CN
China
Prior art keywords
disease
alle
chain
mice
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN01822215A
Other languages
English (en)
Chinese (zh)
Other versions
CN1529605A (zh
Inventor
D·哈拉特斯
J·乔治
G·哈佩恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CANALIS-HAEMALIS BIOGROWTH Ltd
Original Assignee
CANALIS-HAEMALIS BIOGROWTH Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22956589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100577174(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CANALIS-HAEMALIS BIOGROWTH Ltd filed Critical CANALIS-HAEMALIS BIOGROWTH Ltd
Publication of CN1529605A publication Critical patent/CN1529605A/zh
Application granted granted Critical
Publication of CN100577174C publication Critical patent/CN100577174C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1787—Unsaturated ethers containing hydroxy or O-metal groups containing six-membered aromatic rings and having unsaturation outside the aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN01822215A 2000-11-24 2001-11-22 含有限定的氧化磷脂的组合物 Expired - Lifetime CN100577174C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25257400P 2000-11-24 2000-11-24
US60/252,574 2000-11-24

Publications (2)

Publication Number Publication Date
CN1529605A CN1529605A (zh) 2004-09-15
CN100577174C true CN100577174C (zh) 2010-01-06

Family

ID=22956589

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01822215A Expired - Lifetime CN100577174C (zh) 2000-11-24 2001-11-22 含有限定的氧化磷脂的组合物

Country Status (9)

Country Link
EP (2) EP1341543A4 (enExample)
JP (3) JP4162486B2 (enExample)
KR (1) KR100865142B1 (enExample)
CN (1) CN100577174C (enExample)
AU (2) AU2002218461B2 (enExample)
CA (1) CA2429817C (enExample)
IL (1) IL156015A0 (enExample)
MX (1) MXPA03004517A (enExample)
WO (1) WO2002041827A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
KR100865142B1 (ko) * 2000-11-24 2008-10-24 바스큘라 바이오제닉스 리미티드 죽상 경화증의 예방 및 치료를 위해 정의된 산화 인지질을사용하는 방법 및 이를 함유하는 조성물
AU2003243806A1 (en) * 2002-07-15 2004-02-02 Bernd Binder Lipid oxidation products for inhibiting inflammation
AU2007200090B2 (en) * 2004-07-09 2011-09-22 Vascular Biogenics Ltd. Improved Process for the Preparation of Oxidized Phospholipids
US7807847B2 (en) * 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
MX2007000361A (es) * 2004-07-09 2008-03-05 Vascular Biogenics Ltd Proceso mejorado para la preparacion de fosfolipidos oxidados.
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
WO2009116750A2 (ko) * 2008-03-17 2009-09-24 이화여자대학교 산학협력단 혈관 재협착방지 스텐트 코팅용 조성물 및 이를 이용해 제조된 스텐트
NZ591107A (en) 2008-08-12 2012-08-31 Zinfandel Pharmaceuticals Inc Method of identifying disease risk factors
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
US8999960B2 (en) 2008-10-08 2015-04-07 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
AU2009312355C1 (en) 2008-11-06 2016-02-18 Vascular Biogenics Ltd. Oxidized lipid compounds and uses thereof
WO2011083469A1 (en) * 2010-01-05 2011-07-14 Vascular Biogenics Ltd. Treatment with vb-201
US9102666B2 (en) 2011-01-10 2015-08-11 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating Alzheimer's disease
CN103874485B (zh) 2011-09-01 2017-06-09 脉管生物生长有限公司 氧化的磷脂的制剂和剂型
AU2013274406B2 (en) * 2012-06-11 2017-02-02 The Cleveland Clinic Foundation Treatment and prevention of cardiovascular disease and thrombosis
ES2855299T3 (es) 2014-11-26 2021-09-23 Vascular Biogenics Ltd Lípidos oxidados y tratamiento o prevención de la fibrosis
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660855A (en) * 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
CH642665A5 (en) 1979-02-08 1984-04-30 Rudolf Berchtold Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides
US4329302A (en) * 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
DE3307925A1 (de) * 1983-03-05 1984-09-06 A. Nattermann & Cie GmbH, 5000 Köln Neue 0-acyl-alkandiol-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4614796A (en) * 1983-03-25 1986-09-30 Nippon Shinyaku Co., Ltd. Liposome and method of manufacture therefor
JPS60100544A (ja) * 1983-11-08 1985-06-04 Ono Pharmaceut Co Ltd 新規なグリセリン誘導体，その製造方法及びその誘導体を含有する薬剤
JPS60104066A (ja) * 1983-11-10 1985-06-08 Ono Pharmaceut Co Ltd グリセリン誘導体
US5869534A (en) 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4827011A (en) * 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
EP0225129B1 (en) * 1985-11-29 1989-05-24 Takeda Chemical Industries, Ltd. Phospholipid derivatives, their production and use
WO1987005904A1 (en) * 1986-03-24 1987-10-08 The University Of Sydney Antigenic analogues of platelet activating factor (paf)
JPS6354386A (ja) * 1986-08-26 1988-03-08 Takeda Chem Ind Ltd リン脂質およびその用途
JPH01258691A (ja) * 1988-04-06 1989-10-16 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
ES2019552A6 (es) * 1990-04-11 1991-06-16 Menarini Lab Procedimiento para la preparacion de glicerofosfolipidos.
US5561052A (en) 1992-06-18 1996-10-01 Koike; Katsumasa Process for detecting oxidized lipids and process for forming oxidized lipids
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
FR2714382B1 (fr) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
WO1995020654A1 (en) 1994-01-31 1995-08-03 The Institute Of Cancer Research: Royal Cancer Hospital Folding proteins
WO1995023592A1 (en) * 1994-03-04 1995-09-08 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
JP3364313B2 (ja) * 1994-03-22 2003-01-08 株式会社トクヤマ ポルフィリン／インジウム錯体及び陰イオン感応膜
US6156500A (en) 1995-02-10 2000-12-05 Millennium Pharmaceuticals, Inc. Methods for the treatment and diagnosis of cardiovascular disease
US6261597B1 (en) 1995-08-31 2001-07-17 Seymour J. Kurtz Method for treating periodontal disease
US6114395A (en) 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
US6034102A (en) 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6096291A (en) 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US5935577A (en) 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
US5945308A (en) 1998-04-03 1999-08-31 Incyte Pharmaceuticals, Inc. Human oxidized LDL receptor
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
US6701176B1 (en) 1998-11-04 2004-03-02 Johns Hopkins University School Of Medicine Magnetic-resonance-guided imaging, electrophysiology, and ablation
KR100865142B1 (ko) * 2000-11-24 2008-10-24 바스큘라 바이오제닉스 리미티드 죽상 경화증의 예방 및 치료를 위해 정의된 산화 인지질을사용하는 방법 및 이를 함유하는 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660855A (en) * 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
the bind of oxidized Low density liporoproein to mouseCD36ismediated in part by oxidized phospholipids thatareassociatedwith both the lipid and protein moieties ofthelipoprotein. BOULLIER等.The Journall of Biological Chemistry,Vol.275 No.13. 2000 *

Also Published As

Publication number Publication date
WO2002041827A9 (en) 2003-05-30
KR20030077543A (ko) 2003-10-01
WO2002041827A3 (en) 2002-10-10
MXPA03004517A (es) 2004-03-26
CN1529605A (zh) 2004-09-15
WO2002041827A2 (en) 2002-05-30
EP1341543A2 (en) 2003-09-10
JP4162486B2 (ja) 2008-10-08
IL156015A0 (en) 2003-12-23
AU2002218461B2 (en) 2006-09-07
AU1846102A (en) 2002-06-03
JP2012149075A (ja) 2012-08-09
KR100865142B1 (ko) 2008-10-24
EP2425841A1 (en) 2012-03-07
JP5001906B2 (ja) 2012-08-15
JP2008222726A (ja) 2008-09-25
EP1341543A4 (en) 2009-09-02
JP2004537498A (ja) 2004-12-16
CA2429817C (en) 2013-02-12
CA2429817A1 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
CN100577174C (zh) 含有限定的氧化磷脂的组合物
US7186704B2 (en) Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
JP4191997B2 (ja) アテローム性動脈硬化を防止および処置するために斑関連分子を用いる方法および斑関連分子を含有する組成物
JP2003500362A (ja) 免疫反応の調節および炎症性疾患の治療のための方法および組成物
HK1164121A (en) Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
IL176976A (en) Use of oxygenated phospholipids defined for the preparation of a medicinal product for the treatment of atherosclerosis and other vascular diseases
HK1088234B (en) Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: Israel Modein

Patentee after: Canalis-Haemalis Biogrowth Ltd.

Address before: Ashdod

Patentee before: Canalis-Haemalis Biogrowth Ltd.

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20100106